BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S
53 results:

  • 1. Novel Pathways between Invasiveness Modulators in Breast cancer Single Cells.
    Eliceiri GL
    Crit Rev Eukaryot Gene Expr; 2024; 34(2):73-75. PubMed ID: 38073443
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Association of the m
    Li Y; Cao J; Wang J; Wu W; Jiang L; Sun X
    Cancer; 2024 Feb; 130(3):356-374. PubMed ID: 37861451
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Osimertinib and anti-her3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.
    Vicencio JM; Evans R; Green R; An Z; Deng J; Treacy C; Mustapha R; Monypenny J; Costoya C; Lawler K; Ng K; De-Souza K; Coban O; Gomez V; Clancy J; Chen SH; Chalk A; Wong F; Gordon P; Savage C; Gomes C; Pan T; Alfano G; Dolcetti L; Chan JNE; Flores-Borja F; Barber PR; Weitsman G; Sosnowska D; Capone E; Iacobelli S; Hochhauser D; Hartley JA; Parsons M; Arnold JN; Ameer-Beg S; Quezada SA; Yarden Y; Sala G; Ng T
    Cell Death Dis; 2022 Mar; 13(3):274. PubMed ID: 35347108
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
    Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
    Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. her3 Is an Actionable Target in Advanced Prostate cancer.
    Gil V; Miranda S; Riisnaes R; Gurel B; D'Ambrosio M; Vasciaveo A; Crespo M; Ferreira A; Brina D; Troiani M; Sharp A; Sheehan B; Christova R; Seed G; Figueiredo I; Lambros M; Dolling D; Rekowski J; Alajati A; Clarke M; Pereira R; Flohr P; Fowler G; Boysen G; Sumanasuriya S; Bianchini D; Rescigno P; Aversa C; Tunariu N; Guo C; Paschalis A; Bertan C; Buroni L; Ning J; Carreira S; Workman P; Swain A; Califano A; Shen MM; Alimonti A; Neeb A; Welti J; Yuan W; de Bono J;
    Cancer Res; 2021 Dec; 81(24):6207-6218. PubMed ID: 34753775
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Poor prognosis of male triple-positive breast cancer patients: a propensity score matched SEER analysis and molecular portraits.
    Wang B; Wang H; Zhao A; Zhang M; Yang J
    BMC Cancer; 2021 May; 21(1):523. PubMed ID: 33964913
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Associations of Socioeconomic Status, Public vs Private Insurance, and Race/Ethnicity With Metastatic Sarcoma at Diagnosis.
    Diessner BJ; Weigel BJ; Murugan P; Zhang L; Poynter JN; Spector LG
    JAMA Netw Open; 2020 Aug; 3(8):e2011087. PubMed ID: 32766799
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal cancer.
    Löffler MW; Nussbaum B; Jäger G; Jurmeister PS; Budczies J; Pereira PL; Clasen S; Kowalewski DJ; Mühlenbruch L; Königsrainer I; Beckert S; Ladurner R; Wagner S; Bullinger F; Gross TH; Schroeder C; Sipos B; Königsrainer A; Stevanović S; Denkert C; Rammensee HG; Gouttefangeas C; Haen SP
    Front Immunol; 2019; 10():2526. PubMed ID: 31803175
    [No Abstract]    [Full Text] [Related]  

  • 9. EGFR and her3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients.
    Scharpenseel H; Hanssen A; Loges S; Mohme M; Bernreuther C; Peine S; Lamszus K; Goy Y; Petersen C; Westphal M; Glatzel M; Riethdorf S; Pantel K; Wikman H
    Sci Rep; 2019 May; 9(1):7406. PubMed ID: 31092882
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Hybrid supracricoid partial laryngectomy with cricohyoidoepiglottopexy via transoral robotic surgery.
    Nakayama M; Holsinger FC; Orosco RK
    Laryngoscope; 2019 Sep; 129(9):2065-2070. PubMed ID: 30569529
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.
    Wang W; Zhao HF; Yao TF; Gong H
    Invest New Drugs; 2019 Feb; 37(1):175-183. PubMed ID: 30353245
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses.
    Liang WS; Dardis C; Helland A; Sekar S; Adkins J; Cuyugan L; Enriquez D; Byron S; Little AS
    Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30322893
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer.
    Gibson AJW; Li H; D'Silva A; Tudor RA; Elegbede AA; Otsuka SM; Bebb DG; Cheung WY
    Med Oncol; 2018 Aug; 35(9):117. PubMed ID: 30073425
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast cancer Patients.
    Keup C; Mach P; Aktas B; Tewes M; Kolberg HC; Hauch S; Sprenger-Haussels M; Kimmig R; Kasimir-Bauer S
    Clin Chem; 2018 Jul; 64(7):1054-1062. PubMed ID: 29769179
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate cancer.
    McClinch K; Avelar RA; Callejas D; Izadmehr S; Wiredja D; Perl A; Sangodkar J; Kastrinsky DB; Schlatzer D; Cooper M; Kiselar J; Stachnik A; Yao S; Hoon D; McQuaid D; Zaware N; Gong Y; Brautigan DL; Plymate SR; Sprenger CCT; Oh WK; Levine AC; Kirschenbaum A; Sfakianos JP; Sears R; DiFeo A; Ioannou Y; Ohlmeyer M; Narla G; Galsky MD
    Cancer Res; 2018 Apr; 78(8):2065-2080. PubMed ID: 29358171
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.
    Bandyopadhyay A; Favours E; Phelps DA; Pozo VD; Ghilu S; Kurmashev D; Michalek J; Trevino A; Guttridge D; London C; Hirotani K; Zhang L; Kurmasheva RT; Houghton PJ
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29080385
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Clinical manifestations and STK11 germline mutations in Taiwanese patients with Peutz-Jeghers syndrome.
    Chiang JM; Chen TC
    Asian J Surg; 2018 Sep; 41(5):480-485. PubMed ID: 28869103
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
    Mora J; Castañeda A; Perez-Jaume S; Lopez-Pousa A; Maradiegue E; Valverde C; Martin-Broto J; Garcia Del Muro X; Cruz O; Cruz J; Martinez-Trufero J; Maurel J; Vaz MA; de Alava E; de Torres C
    Br J Cancer; 2017 Sep; 117(6):767-774. PubMed ID: 28787430
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. [A randomized study of intensity-modulated radiation therapy versus three dimensional conformal radiation therapy for pelvic radiation in patients of post-operative treatment with gynecologic malignant tumor].
    Ni J; Yin ZM; Yuan SH; Liu NF; Li L; Xu XX; Lou HM
    Zhonghua Fu Chan Ke Za Zhi; 2017 Mar; 52(3):168-174. PubMed ID: 28355688
    [No Abstract]    [Full Text] [Related]  


    [Next]

    of 3.